Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura

NCT ID: NCT01754545

Last Updated: 2012-12-21

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-09-30
• Study Completion Date: 2012-11-30

Brief Summary

Congenital thrombotic thrombocytopenic purpura (TTP), also called Upshaw-Schulman Syndrome or hereditary or familial TTP is a rare, but severe disease. The purpose of this study is to determine how infusions of plasma to patients with congenital TTP correlate with symptoms and signs of activity of the disease, and to determine why some patients need more frequent infusions of plasma than others to prevent acute attacks of the disease.

Detailed Description

Patients with congenital TTP have an inherited lack of function or amount of a protein in plasma called ADAMTS13, that otherwise is responsible for cleaving large von Willebrand-molecules into smaller parts. The patients suffer recurrent attacks of clotting of small blood vessels, that can cause damage to major organs, including the central nervous system. Acute attacks can be treated successfully with infusions of human plasma, and some patients also receive regular plasma therapy for prevention of acute attacks. A small group of patients receive preventive plasma infusions twice or more weekly, indicating a much higher need for plasma than what is otherwise recommended for preventive therapy. Do these patients have an ongoing activity of their disease despite a stimulus? Or a higher turn-over of transfused ADAMTS13? Have these patients developed antibodies against transfused ADAMTS13? Are any symptoms correlated with signs of disease activity?

Conditions

Purpura, Thrombotic Thrombocytopenic

Keywords

Infusions, Intravenous; Plasma; ADAMTS-13 protein, human

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Octaplas infusion and placebo (group 1)

Active treatment with randomly assigned 400 ml octaplas intravenously 2-3 times a week and 400 ml placebo (for octaplas)intravenously 2-3 times a week over two weeks.

Group Type: EXPERIMENTAL

Octaplas infusion and placebo (group 1)

Intervention Type: DRUG

Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.

Octaplas infusion and placebo (group 2)

Active treatment with randomly assigned 400 ml octaplas intravenously once and 400 ml placebo (for octaplas)intravenously twice in two separate intervention weeks

Group Type: EXPERIMENTAL

Octaplas infusion and placebo (group 2)

Intervention Type: DRUG

Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.

Interventions

Octaplas infusion and placebo (group 1)

Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.

Intervention Type: DRUG

Octaplas infusion and placebo (group 2)

Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.

Intervention Type: DRUG

Other Intervention Names

ATC B05A A02; Solvent/detergent plasma; Human plasma; ATC B05A A02; Solvent/detergent plasma; Human plasma

Eligibility Criteria

Inclusion Criteria

• Confirmed diagnosis of congenital TTP
• On regular prophylactic plasma treatment: > Once weekly (group 1) or >1 <3 times monthly (group 2)
• Between 18 and 65 years
• Capable of understanding and complying with the protocol

Exclusion Criteria

• Pregnancy
• Acute bout of TTP requiring daily plasma infusions or -exchange for more than 3 days, within the last 2 weeks before intervention period

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Norwegian University of Science and Technology

OTHER

Sponsor Role: collaborator

St. Olavs Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Anne S von Krogh, MD

Role: PRINCIPAL_INVESTIGATOR

St. Olavs Hospital

Other Identifiers

133995

Identifier Type: -

Identifier Source: org_study_id